November 2022

L'incidence des infections opportunistes chez les patients atteints de rhumatisme psoriasique traités avec des agents biologiques et des agents synthétiques ciblés : Une revue systématique et une méta-analyse

Front Pharmacol 2022;13:992713 doi: 10.3389/fphar.2022.992713

This is the largest meta-analysis to date, assessing the risk of OIs (Opportunistic infection) in patients with PsA. In coming to this conclusion, a systematic review and meta-analysis was undertaken to estimate the incidence of OIs following treatment with b- and tsDMARDs.

Keywords:

September 2022

Olokizumab contre placebo ou adalimumab dans la polyarthrite rhumatoïde

N Engl J Med. 2022;387(8):715–726. doi: 10.1056/NEJMoa2201302

Phase 3 trial of olokizumab, a direct inhibitor of the IL-6 ligand, demonstrates superiority to placebo with respect to an ACR20 response at week 12 and noninferiority to adalimumab (all combined with methotrexate), in patients with RA.

Keywords:

May 2022

Deux essais de phase 3 sur le baricitinib pour l'alopécie areata

N Engl J Med. 2022. Epub ahead of print doi: 10.1056/NEJMoa2110343

Phase 3 trials in patients with severe alopecia areata show that baricitinib is superior to placebo with respect to hair regrowth at 36 weeks.
Alopecia areata is characterised by nonscarring hair loss that can affect any hair-bearing site. Although mild cases of this emotionally- and psychosocially-distressing autoimmune disease may resolve within 12 months, more severe forms of the disease are unlikely to remit without treatment.

Keywords: